Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alzamend Neuro Inc (NQ: ALZN )

2.050 -0.040 (-1.91%)
Streaming Delayed Price Updated: 12:54 PM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alzamend Neuro Inc

< Previous 1 2 3 Next >
Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Announces Pricing of Initial Public Offering
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Disease
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today
From Alzamend Neuro
Via Business Wire
Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer’s Disease
From Ault Global Holdings, Inc.
Via Business Wire
Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer’s Disease
From Alzamend Neuro
Via Business Wire
Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million
From Alzamend Neuro, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.